Activity of toremifene in sporadic desmoid-type fibromatosis.

10033 Background: Hormoneal therapy is one of the most common conservative approaches to desmoid-type fibromatosis (DF). Tamoxifene has been so far the preferred compound. Anecdotal cases treated by Toremifene (T) have also been described. Its mechanism of action is not completely understood, but a possible role in regulating the level of TGF-β and its receptors has been suggested. Aim of the study was to further investigate the feasibility and activity of T in DF. Methods: All consecutive patients affected by sporadic DF, either primarily or secondarily treated with T on a named basis, were prospectively collected. Indication for therapy were either progressive disease and/or pain. Drug schedule was 180 mg daily, until progression or toxicity. Disease assessment was performed by contrast-enhanced MRI or CT scan, pain evaluation by a visual analog scale (VAS) every 3 months. Response was evaluated either by RECIST and/or symptomatic relief. Results: Between 2008 and 2010, 27 patients (F/M ratio = 2.9) wer...